The margin for error in the US homeopathic industry could spread rather than shrink with the Food and Drug Administration withdrawing a policy guide that for three decades allowed sales of the products before it finalizes a guidance on compliance with agency regulations.
In the revised draft guidance it published the same day it withdrew Compliance Policy Guide 400